Last reviewed · How we verify
Test treatment : V0116 transdermal patch — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Test treatment : V0116 transdermal patch (Test treatment : V0116 transdermal patch) — Pierre Fabre Medicament.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Test treatment : V0116 transdermal patch TARGET | Test treatment : V0116 transdermal patch | Pierre Fabre Medicament | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Test treatment : V0116 transdermal patch CI watch — RSS
- Test treatment : V0116 transdermal patch CI watch — Atom
- Test treatment : V0116 transdermal patch CI watch — JSON
- Test treatment : V0116 transdermal patch alone — RSS
Cite this brief
Drug Landscape (2026). Test treatment : V0116 transdermal patch — Competitive Intelligence Brief. https://druglandscape.com/ci/test-treatment-v0116-transdermal-patch. Accessed 2026-06-09.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing